Inhibikase Therapeutics (IKT) Change in Accured Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Change in Accured Expenses data on file, last reported at $43372.0 in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 94.79% year-over-year to $43372.0 in Q1 2026; TTM through Mar 2026 was $611405.0, a 39.2% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, up 233.57% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $43372.0, down from $424899.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for IKT reached as high as $858240.0 in Q1 2022 and fell as low as -$1.3 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged $82876.1 across 5 years, with a median of $132394.0 in 2022.
• Across the five-year window, Change in Accured Expenses surged 15605.69% in 2022 and sank 273.47% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $132394.0 in 2022, then surged by 203.44% to $401740.0 in 2023, then rose by 29.1% to $518656.0 in 2024, then declined by 18.08% to $424899.0 in 2025, then plunged by 89.79% to $43372.0 in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were $43372.0 in Q1 2026, $424899.0 in Q4 2025, and $718197.0 in Q3 2025.